European Parliament session

ECPC

EUROPEAN PARLIAMENT SESSION – HTA & ACCESS TO INNOVATIVE ONCOLOGY DRUGS IN EUROPE

Organised by ECPC in collaboration with CDDF

TITLE
Health Technology Assessment and Access to Innovative Oncology Drugs in Europe

ORGANISERS
European Cancer Patient Coalition and Cancer Drug Development Forum

HOST
MEP Elisabetta Gardini

DATE
Tuesday, 25th September – 14:30 – 16:30

VENUE
European Parliament, Room A5E-2

DESCRIPTION
In light of the European Commission legislative proposal for future EU cooperation on Health Technology Assessment, the European Cancer Patient Coalition and Cancer Drug Development Forum is hosting a timely high-level discussion together with Elisabetta Gardini MEP. It will bring together stakeholders and policymakers to highlight the importance of a more harmonised approach to Health Technology Assessment for ensuring timely access to innovative oncology diagnostics and treatments. Innovative healthcare technologies offer the potential to improve the lives of many people living with cancer. Ensuring effective innovations are accessible and affordable to all patients is a challenge facing all cancer stakeholders. Very few HTA agencies in Europe involve patients in their assessments and, where public engagement is sought, the approached vary. The European Commission’s proposal seeks to dismantle barriers to involving patients in HTA, by creating established methods for providing patient evidence, but more robust patient engagement schemes are needed at both the EU and Member State levels.

REGISTRATION
Register online: https://docs.google.com/forms/d/e/1FAIpQLSdD12KqSEPlmFZ9fgyGo_vTqnB3iJZUCK7SgjmRfaq9FUSTTw/viewform

DRAFT PROGRAMME

WELCOME

Overview of HTA proposal

ECPC achievements in HTA advocacy

Patient involvement in HTA in Member States

Member State Perspective

Innovation Panel

  • Academic Perspective
  • Medical Oncologist Perspective
  • How to create a win-win solution
  • HTA and reimbursement
  • Mandatory uptake of Joint Clinical Assessments

Panel debate and Q&A with the audience

CLOSING REMARKS